Pulmonary sarcoidosis. Sarcoidosis of lung
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Patients receive capsules containing 30 mg of dried saffron extract (Duralife Faran Chemie®) twice a day for two months. Intervention 2: Control
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: People over 18 years of age, people with pulmonary sarcoidosis concomitant sleep disorder (PSQI = 5) who have signed a consent form to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy breastfeeding central nervous system disease (stroke, epilepsy, tumor, history of neurological manipulation), taking sedative-hypnotic drugs (antihistamines, benzodiazepines) taking stimulant drugs allergy to saffron or a combination of formulations, having parasomnias sleep problems related to shift work taking fluvoxamine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of sleepiness during the day. Timepoint: At the start and end of the study. Method of measurement: Epworth sleepiness scale(ESS) criterion.;Fatigue state. Timepoint: At the start and end of the study. Method of measurement: Fatigue assessment Scale(FAS )AND Patient reported outcomes Measurement Information System ( PROMIS )criteria.;Quality of life. Timepoint: At the start and end of the study. Method of measurement: SF-12 criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary function of patients. Timepoint: At the start and end of the study. Method of measurement: Spirometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Moghimi Dehkordi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed